Exelixis | EXEL - Current Assets


Exelixis reported $1.4B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 1.03B 13.64M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
AstraZeneca USD 29.94B 1B Sep/2025
Bayer EUR 32.88B 873M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Eisai JPY 790.7B 27.55B Sep/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Exelixis USD 1.4B 221.5M Sep/2025
Genmab DKK 3.91B 127M Jun/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.6B 427M Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Xencor USD 518.44M 5.29M Sep/2025